MedTrace Logo

Lamictal TM, Haloperidol Decanoate in Schizophrenia

NCT00947375 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 335

Last updated 2009-07-28

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind, placebo-controlled, study.

Nadir A.Aliyev \& Zafar N.Aliyev

Central Mental Clinic for Outpatients of Baku city of Azerbaijan Republic

Abstract:

OBJECTIVE: The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol decanoate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.

Conditions

Interventions

DRUG

Lamictal TM

First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.

DRUG

Haloperidol Decanoate

Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.

Sponsors & Collaborators

  • Central Mental Clinic for Outpatients of Baku City

    lead OTHER

Principal Investigators

  • Nadir A Aliyev, PHD, MD · Outpatient service

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-01-31
Completion
2007-01-31

Countries

  • Azerbaijan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947375 on ClinicalTrials.gov